Mp60-20 Feasibility Study of Adcs Targeting Trop-2, Her2, and Cd46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the Prostate

You have accessJournal of UrologyProstate Cancer: Advanced (Including Drug Therapy) III (MP60)1 May 2024MP60-20 FEASIBILITY STUDY OF ADCS TARGETING TROP-2, HER2, AND CD46 IN DUCTAL ADENOCARCINOMA AND INTRADUCTAL CARCINOMA OF THE PROSTATE Xingming Wang, Lin Qi, Minfeng Chen, Ye Zhang, Xiaomei Gao, and Yi Cai Xingming WangXingming Wang , Lin QiLin Qi , Minfeng ChenMinfeng Chen , Ye ZhangYe Zhang , Xiaomei GaoXiaomei Gao , and Yi CaiYi Cai View All Author Informationhttps://doi.org/10.1097/01.JU.0001008804.84010.ec.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Ductal Adenocarcinoma (DAC), as well as Intraductal Carcinoma of the prostate (IDC-P), have poor oncologic outcomes and could be lethal in patients suffering from Prostate Cancer (PCa). DACs and patients with IDC-P respond poorly to current conventional therapy and remain in poor prognosis undergoing androgen deprivation therapy (ADT) combination androgen receptor (AR) inhibitors. Antibody-drug conjugate (ADC) enables accurate and efficient elimination of cancer cells, and has become one of the hotspots in the research of anticancer strategies, however, no ADCs on the market for the time being in the field of PCa. Consequently, the objective of this study was to investigate the expression of some ADC targets of interest, TROP-2, HER2, and CD46, in DAC and IDC-P samples, and indirectly to perform a preliminary pre-feasibility analysis for the future availability of ADC therapy for DAC and IDC-P patients. METHODS: The study was conducted on 87 DAC or IDC-P patients without any treatment and 97 PAC patients with a Gleason score ≥8 of prostate biopsies and prostatectomy samples between August 2017 and August 2022. The differential protein expression levels of TROP-2, HER2 and CD46 in DAC/IDC-P, Prostatic Acinar Adenocarcinoma (PAC) and normal prostate tissues were detected by immunohistochemical staining, indirectly reflecting the feasibility of applying ADC treatments targeting the above targets in patients with DAC or/and IDC-P. RESULTS: TROP-2 expression was significantly higher in DAC/IDC-P tissues than in pure PAC tissues (73.4 vs 47.0, p<0.001), and was also higher in PAC tissues coexisting with DAC/IDC-P than in pure PAC tissues (64.4 vs 47.0, p=0.020). HER2 expression was generally low in all components of prostate cancer tissues, although HER2 expression was higher in DAC/IDC-P tissues than in pure PAC tissues (9.8 vs 3.9, p=0.004). CD46 expression in DAC/IDC-P tissues was significantly higher than both adjacent PAC tissues to DAC/IDC-P, and also significantly higher than that in pure PAC tissues (30.6 vs 16.8, p=0.002, and 30.6 vs 20.4, p=0.024, respectively). CONCLUSIONS: In DAC and IDC-P tissues, the expression of TROP-2, HER2, and CD46 was higher than that in pure PAC tissues and normal prostate cancer. These results suggest that ADCs targeting all three targets hold promise as potential future treatments for DAC/IDC-P, especially those targeting TROP-2 and CD46, as well as early diagnosis and non-invasive visualization. Source of Funding: This research was supported by the key Research and Development program of Hunan Province (2021SK2014), the National Natural Science Foundation of China(82272907, 81974397) and the clinical research foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA; 2022LNJJ13) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1008 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Xingming Wang More articles by this author Lin Qi More articles by this author Minfeng Chen More articles by this author Ye Zhang More articles by this author Xiaomei Gao More articles by this author Yi Cai More articles by this author Expand All Advertisement PDF downloadLoading ...